Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RM601
- Development stage
- Preclinical
- Lead developer
- Guangzhou Ruifeng Biological Technology
- Modality
- Cell Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Parenteral
01
Overview
RM601 is a preclinical-stage ex vivo gene-editing therapeutic candidate being developed by Guangzhou Reforgene Medicine. The program is designed to address undisclosed indications categorized under "Other System" diseases. As an ex vivo gene therapy, the treatment involves the genetic modification of a patient's cells outside the body, which are then re-administered to achieve a therapeutic effect. While the specific molecular target and the precise gene-editing technology (such as CRISPR/Cas9 or base editing) utilized for RM601 have not been publicly disclosed, the asset is part of Reforgene's broader pipeline focused on precision genetic medicines.
- Other names
- RM601RM-601RM 601
Beyond the preview
Go deeper on RM601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RM601.